Medivir: Deal for Remetinostat Getting Close? - Redeye

Redeye is positively surprised by the news of renegotiated terms for remetinostat, which we believe significantly increases the likelihood of a licensing deal. Pending the outcome of business development activities for the project, we will reconsider our base case for a potential upgrade.

Länk till analysen i sin helhet: https://www.redeye.se/research/818654/medivir-deal-for-remetinostat-getting-close?utm_source=finwire&utm_medium=RSS